JUNS (Jupiter Neurosciences) OCF Yield %: -56.88 (As of Jul. 01, 2026)


JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.21
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences OCF Yield %?

Jupiter Neurosciences JUNS -0.24% 4 OCF Yield % is -56.88 as of Jul. 01, 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review. Among 1,415 Biotechnology companies, Jupiter Neurosciences ranks worse than 85.09% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Jupiter Neurosciences's Trailing 12-Month Cash Flow from Operations is $-5.78 Mil, and Market Cap is $10.17 Mil. Therefore, Jupiter Neurosciences's OCF Yield % for today is -56.88%.

The historical rank and industry rank for Jupiter Neurosciences's OCF Yield % or its related term are showing as below:

JUNS' s OCF Yield % Range Over the Past 10 Years
Min: -77.61   Med: -40.51   Max: -13.38
Current: -56.88


During the past 7 years, the highest OCF Yield % of Jupiter Neurosciences was -13.38%. The lowest was -77.61%. And the median was -40.51%.

JUNS's OCF Yield % is ranked worse than
85.09% of 1415 companies
in the Biotechnology industry
Industry Median: -8.19 vs JUNS: -56.88

Jupiter Neurosciences's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Jupiter Neurosciences OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Jupiter Neurosciences OCF Yield % Related Terms


Jupiter Neurosciences OCF Yield % Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences OCF Yield % Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 -1.10 -15.41

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.06 -9.32 -7.65 -26.96 -41.97

JUNS vs ZEOX, LEXX, GDTC: OCF Yield % Comparison

For the Biotechnology subindustry, Jupiter Neurosciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jupiter Neurosciences OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Jupiter Neurosciences's OCF Yield % falls into.


JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Jupiter Neurosciences's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-5.414 / 35.13492
=-15.41%

Jupiter Neurosciences's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-1.432 * 4 / 13.6489122
=-41.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -56.88 mean?
Jupiter Neurosciences (JUNS) has a OCF Yield % of -56.88 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Jupiter Neurosciences and its competitors. According to the industry distribution chart, Jupiter Neurosciences ranks #1204 out of 1415 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Jupiter Neurosciences' OCF Yield % too high?
Jupiter Neurosciences' current OCF Yield % is -56.88. Based on the distribution chart, Jupiter Neurosciences ranks #1204 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' OCF Yield % compare to ZEOX and LEXX?
According to the Biotechnology industry distribution chart, Jupiter Neurosciences ranks #1204 out of 1415 companies for OCF Yield %. This places Jupiter Neurosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current OCF Yield % is -56.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current OCF Yield % of -56.88. The current OCF Yield % is -56.88. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current OCF Yield % is -56.88 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price